MEX3B

Across TCGA pan-cancer cohorts, MEX3B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MEX3B data layer compared with 22 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MEX3B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MEX3B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, UCEC, and LIHC are the cancer types where MEX3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
UCEC	DFS	Median	II,III,IV	1.000	0.437	.012	24	view →
LIHC	DFS	Median	All	0.075	0.555	<.001	12	view →
KIRP	DFS	Median	All	0.181	0.768	.004	6	view →
BLCA	OS	Median	IV	0.132	0.599	.004	6	view →
LUSC	OS	Median	II,III,IV	0.279	0.742	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MEX3B–ESCA (OS)

Open the ESCA breakdown →